Clinical trials: Hydroxychloroquine
Malignant Solid Tumour
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to…
- Trial name
- NCT01023737
- Testing
- Hydroxychloroquine, Vorinostat
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Immune Thrombocytopenia With Positive ANA Antibodies
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults.
- Trial name
- NCT06479291
- Testing
- Hydroxychloroquine Oral Tablet, Eltrombopag
- Where
- 7 sites in China, Hong Kong and 1 more
- Volunteers
- 126 people
- Sponsor
- Yunfeng Cheng
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Rheumatic Diseases
Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine
Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune…
- Trial name
- NCT04310462
- Testing
- New e-prescribing interface
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Zellweger Syndrome, Peroxisome Biogenesis Disorders
Hydroxychloroquine Administration for Reduction of Pexophagy
A series of N-of-1, crossover, randomized, placebo-controlled, double-blinded trial. Hydroxychloroquine (HCQ) and a crossover to placebo (order is randomized and blinded) will be administered in liquid suspension for 84 days (12…
- Trial name
- HARP (NCT03856866)
- Testing
- Hydroxychloroquine
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- The Hospital for Sick Children
Lupus Nephritis, Children
Multicenter Registry of Pediatric Lupus Nephritis in China
This study is designed to evaluate the efficacy and safety of the current treatment option and outcome of pediatric lupus nephritis patients in China.
- Conditions
- Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment
- Trial name
- NCT03791827
- Testing
- Corticosteroid, Hydroxychloroquine, Cyclophosphamide
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Xiqiang Dang
Surfactant Dysfunction
Hydroxychloroquin (HCQ) in chILD of Genetic Defect
The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary surfactant-associated genes mutations.
- Trial name
- NCT03822780
- Testing
- Hydroxychloroquin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Children's Hospital of Fudan University
COVID-19
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19
New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under attack by the virus.
- Trial name
- NCT04331470
- Testing
- Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Fasa University of Medical Sciences
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sjögren's Syndrome, Xerostomia
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
Chronic inflammation that comprises the exocrine glands' function leads to xerophthalmia and xerostomia in Sjögren's syndrome. The oral consequences range widely and they are related to decreased salivary output.
- Trial name
- NCT00873496
- Testing
- Hydroxychloroquine
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Ege University
COVID-19, Favipiravir
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study.
- Conditions
- COVID-19, Favipiravir, Kaletra, Hydroxychloroquine
- Trial name
- NCT04376814
- Testing
- Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Baqiyatallah Medical Sciences University
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
Nonalcoholic Steatohepatitis
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol…
- Trial name
- NCT05733897
- Testing
- hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Lupus Erythematosus, Systemic
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
The purpose of this study is: 1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood. 2.
- Trial name
- NCT00065806
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Laura Schanberg
COVID-19
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04307693
- Testing
- Lopinavir/ritonavir, Hydroxychloroquine sulfate
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Asan Medical Center
COVID-19
Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has been discovered recently in December 2019 from wuhan city in China to spread in more than 40 countries…
- Trial name
- NCT04323345
- Testing
- Natural Honey, Standard Care
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Misr University for Science and Technology
Pregnancy Related, COVID
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects…
- Conditions
- Pregnancy Related, COVID, Covid-19
- Trial name
- COVID-Preg (NCT04410562)
- Testing
- Hydroxychloroquine
- Where
- 9 sites in Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Systemic Lupus Erythematosus
Study of Anti-Malarials in Incomplete Lupus Erythematosus
This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation…
- Trial name
- SMILE (NCT03030118)
- Testing
- Hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 187 people
- Sponsor
- Milton S. Hershey Medical Center
Coronavirus Infections, Diabetes Mellitus
Covid-19 and Diabetes in West of Algeria
By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019).
- Conditions
- Coronavirus Infections, Diabetes Mellitus, Prevalence, Risk Factors
- Trial name
- COVIDIAB-13 (NCT04412746)
- Testing
- MANAGEMENT OF COVID-19
- Where
- Algeria
- Volunteers
- 100 people
- Sponsor
- Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen